Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04247334 · ClinicalTrials.gov registry record · NA

Inhibitory Control: Effects of Modulation

A NA study, sponsored by Butler Hospital.

Completed
Registry status
NA
Development phase
117
Enrollment target

NCT04247334: Completed NA study, sponsored by Butler Hospital.

NCT04247334 is a NA study that has completed, run by Butler Hospital. The registered enrollment target is 117 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04247334, a NA study, has completed, sponsored by Butler Hospital.

COMPLETED
Registry status
NA
Development phase
117 participants
Enrollment target

Study Summary

Inhibitory control is relevant to many clinical disorders, including substance abuse/dependence, obsessive-compulsive disorder, and attention-deficit hyperactivity disorder. This proposal is designed to assess brain networks related to response inhibition in healthy young adults, and use neuromodulation to change these networks and behavioral performance on a response inhibition task. Having an understanding of the brain mechanisms involved in response inhibition may enable us to improve pre-existing treatments for disorders with inhibitory control difficulties.

Primary Outcome

Changes in resting state connectivity of the inhibitory control information

Interventions

  • DEVICE Transcranial direct current stimulation

Trial Details

FieldValue
Enrollment Target 117 participants
Start Date 2019-11-14
Est. Completion 2024-02-25
Phase NA
Butler Hospital

103 total trials

What the finished NCT04247334 record still lists

NCT04247334 is an interventional study that assigns participants to a tested intervention. The registered 117 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower).

The record links to 0 conditions, and to 1 intervention - of which Transcranial direct current stimulation is the first listed.

NCT04247334 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04247334 about?

NCT04247334 is a clinical study titled "Inhibitory Control: Effects of Modulation". Inhibitory control is relevant to many clinical disorders, including substance abuse/dependence, obsessive-compulsive disorder, and attention-deficit hyperactivity disorder. This proposal is designed to assess brain networks related to response inhibition in healthy young adults, and use neuromodula...

What is the current status of trial NCT04247334?

This trial is currently completed. It is a NA study. The enrollment target is 117 participants. The study started on 2019-11-14. Estimated completion is 2024-02-25.

What interventions are being tested in trial NCT04247334?

The interventions under investigation include: Transcranial direct current stimulation (DEVICE).

Who is sponsoring clinical trial NCT04247334?

This trial is sponsored by Butler Hospital, which has 103 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04247334's enrollment target sits among peer trials

117 807th of 2000 higher than 1,193 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03539822 · 117 participants · Phase 1

    Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies

  • NCT03786692 · 117 participants · Phase 2

    Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC

  • NCT04479696 · 117 participants · NA

    Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors

  • NCT04940585 · 117 participants · NA

    ROSE in Sunset Park

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04247334, the US trial registry maintained by the National Library of Medicine. NCT04247334 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.